Why Is ClearPoint Neuro ( $CLPT) Stock Down -22.53% Today? (Find out why any stock moved today on Tickeron.) CLPT shares plunged roughly 22.5% on Tuesday after a partner's clinical trial setback. The primary catalyst was disappointing 48-month data from gene therapy developer uniQure (QURE) for its Huntington's disease candidate AMT-130. ClearPoint Neuro supplies the MRI-guided navigation platform and SmartFlow cannula used to deliver AMT-130 into the brain, tying its revenue prospects to the program's fate. uniQure shares tumbled roughly 55% on the news, amplifying the sell-off across the cell and gene therapy delivery complex. $ICUI $ISRG $A $NVST
published
Why Is ClearPoint Neuro ( $CLPT) Stock Down -22.53% Today? (Find out why any stock moved today on Tickeron.) CLPT shares plunged roughly 22.5% on Tuesday after a partner's clinical trial setback. The primary catalyst was disappointing 48-month data from gene t
$CLPT$ICUI$ISRG$A$NVST
Latest documented BWB result
$TSLA · $SPY market result
Exit $TSLA PDS with a .60 profit per contract - was willing to hold if $SPY closed under the SMA 50 but not with a close above it
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.